I agree, I don't see why one has to drive a 2160p display with 2160p content. Before all the HD standards came out, lots of people were using scalers (line doublers and quadruplers) to improve the quality of their laserdisc or DVD content on displays way above 480p. For example, the old Sony G90 projector will do about 2500 x 2000. If the past is any indicator, 480p and 1080p material will look even BETTER upscaled on a 2160p display than on a 1080p one.
Yea, I was also working on drug design tools back in 1999, although more at the quantum level. At one point I took a look at what P&G was doing in their computational chemistry group, and it was pretty small (about 8 guys, with a bunch of SGI machines and a Linux cluster) considering the company's size. And I think that pretty much summed up computational drug design at the turn of the millenium: most big companies weren't interested in radically changing their R&D pipelines for a new fangled technology, and the biotech boom was in a slump, so investors were off hibernating. Practically all my end users were government, military, or edu, and almost entirely for materials design than pharmaceuticals.
Just goes to show, being the first person working on a great idea isn't enough: you need to be able to convince some VC's how you're the greatest thing since butter on sliced bread before anyone seems to take any interest.
Slashdot Mirror
I agree, I don't see why one has to drive a 2160p display with 2160p content. Before all the HD standards came out, lots of people were using scalers (line doublers and quadruplers) to improve the quality of their laserdisc or DVD content on displays way above 480p. For example, the old Sony G90 projector will do about 2500 x 2000. If the past is any indicator, 480p and 1080p material will look even BETTER upscaled on a 2160p display than on a 1080p one.
Yea, I was also working on drug design tools back in 1999, although more at the quantum level. At one point I took a look at what P&G was doing in their computational chemistry group, and it was pretty small (about 8 guys, with a bunch of SGI machines and a Linux cluster) considering the company's size. And I think that pretty much summed up computational drug design at the turn of the millenium: most big companies weren't interested in radically changing their R&D pipelines for a new fangled technology, and the biotech boom was in a slump, so investors were off hibernating. Practically all my end users were government, military, or edu, and almost entirely for materials design than pharmaceuticals.
Just goes to show, being the first person working on a great idea isn't enough: you need to be able to convince some VC's how you're the greatest thing since butter on sliced bread before anyone seems to take any interest.